Cardiac Arrest Recovery EEG Study (CARES)
Phase IIB Study of Novel Quantitative Neurodiagnostic Technology in the Early Period After Cardiac Arrest
Panoramica dello studio
Descrizione dettagliata
Cardiac arrest claims over 450,000 lives per year in the United States alone. There is a high incidence of neurological complications amongst survivors, and these represent the leading cause of morbidity.
Over the past several years, the care of these patients has been improved via the introduction of new systemic as well as neurospecific therapies. Speed of institution of therapy appears to be an important factor affecting efficacy. Yet, in the crucial initial hours to days post-arrest, assessment of neurological status in these patients is essentially non-existent.
Thus, there is a need for an objective validated tool to assess prognosis and to track neurological status in the early recovery period. In response to this need, we have developed an EEG based Cortical Health Index (CHI). This EEG-based index incorporates multiple weighted parameters derived from 2 channels (4 scalp electrodes + 1 ground electrode) which are related to neurologic functional recovery. The strength and uniqueness of this approach results from consideration of both the temporal as well as the spectral domains of EEG. Our Phase II results demonstrate that CHI measured within the first 6-hours post-arrest resuscitation is strongly correlated with clinical outcome at hospital discharge in a 30-patient cardiac arrest study. Together with our industry collaborator, we now propose to pursue regulatory approval of the CHI Monitor. Our plan involves a prospective clinical trial involving 4 centers and 100 patients (64 Cardiac Arrest Patients and 36 patients undergoing ICD placement as controls). We will test the ability of CHI to: 1) provide early prediction of subsequent neurological functional outcome of cardiac arrest patients, and 2) provide real-time tracking of brain injury and response to therapy. Successful completion of this project is defined by FDA clearance of the CHI Monitor.
It is our goal that the CHI Monitor will identify patients who could benefit from aggressive intervention, and then track the response to the therapy. Providing this information to the treating physician in the immediate post-resuscitation period represents a major change in care delivery for the cardiac arrest survivor.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21224
- Reclutamento
- Johns Hopkins Bayview Medical Center
-
Investigatore principale:
- Romergryko Geocadin, MD
-
Baltimore, Maryland, Stati Uniti, 21187
- Reclutamento
- Johns Hopkins Hospital
-
Contatto:
- Daniel F Hanley, MD
- Numero di telefono: 410-614-6996
- Email: dhanley@jhmi.edu
-
Investigatore principale:
- Romergryko Geocadin, MD
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23298
- Non ancora reclutamento
- Virginia Commonwealth University
-
Contatto:
- Mary Ann Peberdy, MD
- Numero di telefono: 804-828-4571
- Email: mpeberdy@aol.com
-
Investigatore principale:
- Mary Ann Peberdy, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Medical College of Wisconsin at Froedtert Memorial Luthern Hospital Clinics - Neurology
-
Contatto:
- Michel Torbey, MD,MPH
- Numero di telefono: 414-805-5343
- Email: mtorbey@mcw.edu
-
Investigatore principale:
- Michel Torbey, MD, MPH
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
Cardiac Arrest:
Patients 18 years and older:
- with cardiac arrest in the hospital and successfully resuscitated, or
- with cardiac arrest out of the hospital and successfully resuscitated
ICD patients:
Patients 18 years and older:
- Who are undergoing elective procedure in the electrophysiology laboratory for placement of a cardiac defibrillator and who will most likely undergo induction of ventricular arrhythmia as part of the procedure
Exclusion Criteria:
Cardiac Arrest:
- Cardiac arrest and a known pre-existing cerebral pathology such as brain tumor, cerebral hemorrhage, encephalitis or immediately post-op neurosurgery.
- CNS infection
- Skull defects and scalp diseases that are not amenable to standard EEG testing
ICD patients:
- Known pre-existing cerebral pathology such as brain tumor, cerebral hemorrhage, encephalitis or immediately post-op neurosurgery.
- CNS infection
- Skull defects and scalp diseases that are not amenable to standard EEG testing
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Neil S Rothman, PhD, Infinite Biomedical Technologies - Study Sponsor
- Investigatore principale: Romergryko Geocadin, MD, Johns Hopkins University
- Investigatore principale: Michel Torbey, MD, MPH, Medical College of Wisconsin
- Investigatore principale: Mary Ann Peberdy, MD, Virginia Commonwealth University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- R44HL070129 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .